A 52-year-old man with type 2 diabetes mellitus on metformin monotherapy for 3 years presents with inadequate glycemic control (HbA1c 8.2%). His physician decides to add a second oral hypoglycemic agent. Among the commonly used classes of oral antidiabetic drugs, which is the most common cause of hypoglycemia when used as monotherapy?

## Most Common Cause of Hypoglycemia Among Oral Hypoglycemics **Key Point:** Sulfonylureas are the most common cause of hypoglycemia among all oral antidiabetic agents when used as monotherapy. ### Mechanism of Hypoglycemia Risk Sulfonylureas (e.g., glibenclamide, gliclazide, glipizide) work by: 1. Binding to ATP-sensitive K⁺ channels on pancreatic β-cells 2. Causing depolarization and opening of voltage-gated Ca²⁺ channels 3. Triggering insulin secretion **independent of blood glucose levels** This glucose-independent mechanism means insulin is released even when blood glucose is low, leading to hypoglycemia. ### Comparison of Hypoglycemia Risk Across Oral Agents | Drug Class | Hypoglycemia Risk | Mechanism | |---|---|---| | **Sulfonylureas** | **High (most common)** | **Glucose-independent insulin secretion** | | Meglitinides | Moderate | Rapid, short-acting insulin secretion | | Thiazolidinediones | Very low | Insulin sensitizer; no direct β-cell stimulation | | DPP-4 inhibitors | Very low | GLP-1 dependent; glucose-responsive | | SGLT-2 inhibitors | Very low | Renal glucose excretion; no direct insulin effect | | Metformin | Negligible | Decreases hepatic glucose output; no insulin secretion | **High-Yield:** Sulfonylureas account for the majority of drug-induced hypoglycemia cases in clinical practice, especially in elderly patients and those with renal impairment (prolonged drug half-life). ### Clinical Pearl Second-generation sulfonylureas (gliclazide, glipizide) have a lower hypoglycemia risk than first-generation agents (glibenclamide) due to shorter half-lives and more selective β-cell binding, but hypoglycemia remains the most common adverse effect class-wide. ### Why Other Options Do Not Cause Hypoglycemia - **Thiazolidinediones:** Increase insulin sensitivity in muscle and adipose tissue; do not stimulate insulin secretion directly. - **DPP-4 inhibitors:** Enhance GLP-1 action, which is glucose-dependent; insulin is only released when blood glucose is elevated. - **SGLT-2 inhibitors:** Promote urinary glucose excretion; no direct effect on insulin secretion. [cite:KD Tripathi 8e Ch 27]